INGN

$6.20

Market ClosedAs of Mar 17, 8:00 PM UTC

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.20
Potential Upside
5%
Whystock Fair Value$6.51
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen thera...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$168.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-12.43%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.52

Recent News

Zacks
Feb 25, 2026

Inogen Stock Dips Despite Q4 Earnings Beat, Revenues Up Y/Y

INGN posts narrower Q4 loss and 2% revenue rise, but shares dip as U.S. sales and rentals weaken despite international strength.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Feb 25, 2026

Inogen, Inc. Q4 2025 Earnings Call Summary

Moby summary of Inogen, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Feb 25, 2026

Inogen Q4 Earnings Call Highlights

Inogen (NASDAQ:INGN) executives highlighted improving profitability, international momentum, and a broadened product portfolio during the company’s fourth-quarter 2025 earnings call held February 24, 2026. Management also introduced 2026 revenue guidance and disclosed a new $30 million share repurch

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 25, 2026

Inogen Inc (INGN) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Initiatives ...

Inogen Inc (INGN) reports a 4% annual revenue increase and unveils a $30 million share repurchase program, signaling confidence in its growth strategy.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 25, 2026

Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of +27.78% and -0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.